VCNX Vaccinex Inc
Price (delayed)
$5.16
Market cap
$8.91M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.06
Enterprise value
$8.8M
Vaccinex, Inc. is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The Company's lead drug candidate, pepinemab, blocks SEMA4D,
Highlights
Vaccinex's EPS has surged by 95% YoY and by 81% QoQ
Vaccinex's debt has plunged by 67% YoY and by 34% from the previous quarter
Vaccinex's gross profit has soared by 187% from the previous quarter but it has plunged by 57% YoY
Vaccinex's revenue has soared by 187% from the previous quarter but it has plunged by 57% YoY
The quick ratio has plunged by 80% from the previous quarter and by 56% YoY
Key stats
What are the main financial stats of VCNX
Market
Valuations
Earnings
Shares outstanding
1.73M
Market cap
$8.91M
Enterprise value
$8.8M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
26.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
24.73
Revenue
$356,000
EBIT
-$17.76M
EBITDA
-$17.65M
Free cash flow
-$15.77M
Per share
Balance sheet
Liquidity
EPS
-$5.06
Free cash flow per share
-$8.67
Book value per share
-$1.81
Revenue per share
$0.2
TBVPS
$1.3
Total assets
$2.37M
Total liabilities
$5.23M
Debt
$122,000
Equity
-$2.86M
Working capital
-$3.03M
Debt to equity
-0.04
Current ratio
0.42
Quick ratio
0.25
Net debt/EBITDA
0.01
Margins
Efficiency
Dividend
EBITDA margin
-4,956.7%
Gross margin
100%
Net margin
-4,987.9%
Operating margin
-6,072.5%
Return on assets
-446.1%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
-4,987.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VCNX stock price
How has the Vaccinex stock price performed over time
Intraday
-14%
1 week
-8.99%
1 month
7.28%
1 year
-85.89%
YTD
-44.58%
QTD
-20.49%
Financial performance
How have Vaccinex's revenue and profit performed over time
Revenue
$356,000
Gross profit
$356,000
Operating income
-$21.62M
Net income
-$17.76M
Gross margin
100%
Net margin
-4,987.9%
Vaccinex's gross profit has soared by 187% from the previous quarter but it has plunged by 57% YoY
Vaccinex's revenue has soared by 187% from the previous quarter but it has plunged by 57% YoY
The operating margin has plunged by 128% YoY but it has soared by 67% from the previous quarter
Vaccinex's net margin has plunged by 88% YoY but it has soared by 68% from the previous quarter
Growth
What is Vaccinex's growth rate over time
Valuation
What is Vaccinex stock price valuation
P/E
N/A
P/B
N/A
P/S
26.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
24.73
Vaccinex's EPS has surged by 95% YoY and by 81% QoQ
Vaccinex's revenue has soared by 187% from the previous quarter but it has plunged by 57% YoY
VCNX's price to sales (P/S) is 83% less than its 5-year quarterly average of 176.5 and 3.1% less than its last 4 quarters average of 31.6
Efficiency
How efficient is Vaccinex business performance
Vaccinex's return on sales has shrunk by 88% YoY but it has surged by 68% QoQ
Vaccinex's ROA has decreased by 25% YoY but it has increased by 3.3% from the previous quarter
Dividends
What is VCNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VCNX.
Financial health
How did Vaccinex financials performed over time
The total assets is 55% smaller than the total liabilities
The quick ratio has plunged by 80% from the previous quarter and by 56% YoY
VCNX's current ratio has dropped by 72% since the previous quarter and by 47% year-on-year
Vaccinex's debt is 104% more than its equity
VCNX's debt to equity has dropped by 157% since the previous quarter but it has surged by 95% year-on-year
Vaccinex's debt has plunged by 67% YoY and by 34% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.